| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.
|
Cancer Cell
|
2004
|
10.89
|
|
2
|
Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways.
|
Nat Med
|
2011
|
6.21
|
|
3
|
ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation.
|
Nat Cell Biol
|
2008
|
5.19
|
|
4
|
Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer.
|
Nat Clin Pract Oncol
|
2006
|
4.91
|
|
5
|
Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis.
|
Cancer Cell
|
2004
|
4.17
|
|
6
|
p53 regulates epithelial-mesenchymal transition and stem cell properties through modulating miRNAs.
|
Nat Cell Biol
|
2011
|
3.85
|
|
7
|
Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency.
|
Clin Cancer Res
|
2007
|
2.89
|
|
8
|
PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer.
|
Am J Pathol
|
2010
|
2.52
|
|
9
|
Lineage infidelity of MDA-MB-435 cells: expression of melanocyte proteins in a breast cancer cell line.
|
Cancer Res
|
2004
|
2.32
|
|
10
|
Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy.
|
J Clin Oncol
|
2011
|
2.32
|
|
11
|
The Skp2-SCF E3 ligase regulates Akt ubiquitination, glycolysis, herceptin sensitivity, and tumorigenesis.
|
Cell
|
2012
|
2.30
|
|
12
|
Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers.
|
Clin Cancer Res
|
2004
|
2.28
|
|
13
|
14-3-3zeta Cooperates with ErbB2 to promote ductal carcinoma in situ progression to invasive breast cancer by inducing epithelial-mesenchymal transition.
|
Cancer Cell
|
2009
|
2.09
|
|
14
|
PI(3)king apart PTEN's role in cancer.
|
Clin Cancer Res
|
2010
|
2.07
|
|
15
|
Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers.
|
Mol Carcinog
|
2008
|
2.01
|
|
16
|
A robust assay for alternative lengthening of telomeres in tumors shows the significance of alternative lengthening of telomeres in sarcomas and astrocytomas.
|
Clin Cancer Res
|
2005
|
1.95
|
|
17
|
High-resolution fiber-optic microendoscopy for in situ cellular imaging.
|
J Vis Exp
|
2011
|
1.88
|
|
18
|
14-3-3zeta overexpression defines high risk for breast cancer recurrence and promotes cancer cell survival.
|
Cancer Res
|
2009
|
1.74
|
|
19
|
Molecular predictors of response to trastuzumab and lapatinib in breast cancer.
|
Nat Rev Clin Oncol
|
2009
|
1.67
|
|
20
|
Phosphorylation on tyrosine-15 of p34(Cdc2) by ErbB2 inhibits p34(Cdc2) activation and is involved in resistance to taxol-induced apoptosis.
|
Mol Cell
|
2002
|
1.67
|
|
21
|
ErbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin/p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells.
|
Cancer Res
|
2006
|
1.66
|
|
22
|
Breast cancer metastasis: challenges and opportunities.
|
Cancer Res
|
2009
|
1.63
|
|
23
|
Cytokine receptor CXCR4 mediates estrogen-independent tumorigenesis, metastasis, and resistance to endocrine therapy in human breast cancer.
|
Cancer Res
|
2010
|
1.45
|
|
24
|
Targeting Src family kinases in anti-cancer therapies: turning promise into triumph.
|
Trends Pharmacol Sci
|
2011
|
1.45
|
|
25
|
14-3-3 zeta down-regulates p53 in mammary epithelial cells and confers luminal filling.
|
Cancer Res
|
2008
|
1.41
|
|
26
|
Tissue transglutaminase promotes drug resistance and invasion by inducing mesenchymal transition in mammary epithelial cells.
|
PLoS One
|
2010
|
1.36
|
|
27
|
Rad51 overexpression contributes to chemoresistance in human soft tissue sarcoma cells: a role for p53/activator protein 2 transcriptional regulation.
|
Mol Cancer Ther
|
2007
|
1.36
|
|
28
|
ErbB2 promotes Src synthesis and stability: novel mechanisms of Src activation that confer breast cancer metastasis.
|
Cancer Res
|
2005
|
1.35
|
|
29
|
Mechanisms of trastuzumab resistance and their clinical implications.
|
Ann N Y Acad Sci
|
2005
|
1.31
|
|
30
|
Molecular mechanisms of erbB2-mediated breast cancer chemoresistance.
|
Adv Exp Med Biol
|
2007
|
1.27
|
|
31
|
Cancer cell stiffness: integrated roles of three-dimensional matrix stiffness and transforming potential.
|
Biophys J
|
2010
|
1.24
|
|
32
|
Selective inhibition of ErbB2-overexpressing breast cancer in vivo by a novel TAT-based ErbB2-targeting signal transducers and activators of transcription 3-blocking peptide.
|
Cancer Res
|
2006
|
1.21
|
|
33
|
Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone.
|
Cancer
|
2003
|
1.20
|
|
34
|
14-3-3ζ as a prognostic marker and therapeutic target for cancer.
|
Expert Opin Ther Targets
|
2010
|
1.18
|
|
35
|
BikDD eliminates breast cancer initiating cells and synergizes with lapatinib for breast cancer treatment.
|
Cancer Cell
|
2011
|
1.17
|
|
36
|
Mitotic deregulation by survivin in ErbB2-overexpressing breast cancer cells contributes to Taxol resistance.
|
Clin Cancer Res
|
2009
|
1.13
|
|
37
|
Synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces growth arrest in HER2-overexpressing breast cancer cells.
|
Mol Cancer Ther
|
2006
|
1.10
|
|
38
|
ErbB2-mediated Src and signal transducer and activator of transcription 3 activation leads to transcriptional up-regulation of p21Cip1 and chemoresistance in breast cancer cells.
|
Mol Cancer Res
|
2009
|
1.09
|
|
39
|
Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells.
|
Cancer Res
|
2002
|
1.07
|
|
40
|
SRC family kinases as novel therapeutic targets to treat breast cancer brain metastases.
|
Cancer Res
|
2013
|
1.06
|
|
41
|
ErbB2 overexpression correlates with increased expression of vascular endothelial growth factors A, C, and D in human breast carcinoma.
|
Cancer
|
2002
|
1.06
|
|
42
|
Cancer cell migration: integrated roles of matrix mechanics and transforming potential.
|
PLoS One
|
2011
|
1.05
|
|
43
|
Wild-type p53 inhibits nuclear factor-kappaB-induced matrix metalloproteinase-9 promoter activation: implications for soft tissue sarcoma growth and metastasis.
|
Mol Cancer Res
|
2006
|
1.01
|
|
44
|
Vascular endothelial growth factor overexpression by soft tissue sarcoma cells: implications for tumor growth, metastasis, and chemoresistance.
|
Cancer Res
|
2006
|
1.00
|
|
45
|
Evidence that aberrant expression of tissue transglutaminase promotes stem cell characteristics in mammary epithelial cells.
|
PLoS One
|
2011
|
1.00
|
|
46
|
Combined anti-fetal liver kinase 1 monoclonal antibody and continuous low-dose doxorubicin inhibits angiogenesis and growth of human soft tissue sarcoma xenografts by induction of endothelial cell apoptosis.
|
Cancer Res
|
2002
|
0.99
|
|
47
|
Transcriptional repression of protein kinase Calpha via Sp1 by wild type p53 is involved in inhibition of multidrug resistance 1 P-glycoprotein phosphorylation.
|
J Biol Chem
|
2004
|
0.98
|
|
48
|
Ph.D. Training in cancer biology.
|
Cancer Res
|
2008
|
0.97
|
|
49
|
Nucleolin protein interacts with microprocessor complex to affect biogenesis of microRNAs 15a and 16.
|
J Biol Chem
|
2011
|
0.95
|
|
50
|
Upregulation of neutrophil gelatinase-associated lipocalin by ErbB2 through nuclear factor-kappaB activation.
|
Cancer Res
|
2009
|
0.94
|
|
51
|
Needle-based fluorescence endomicroscopy via structured illumination with a plastic, achromatic objective.
|
J Biomed Opt
|
2013
|
0.93
|
|
52
|
A knotty turnabout?: Akt1 as a metastasis suppressor.
|
Cancer Cell
|
2005
|
0.93
|
|
53
|
Microenvironment determinants of brain metastasis.
|
Cell Biosci
|
2011
|
0.93
|
|
54
|
Concomitant targeting of tumor cells and induction of T-cell response synergizes to effectively inhibit trastuzumab-resistant breast cancer.
|
Cancer Res
|
2012
|
0.90
|
|
55
|
Evidence that GTP-binding domain but not catalytic domain of transglutaminase 2 is essential for epithelial-to-mesenchymal transition in mammary epithelial cells.
|
Breast Cancer Res
|
2012
|
0.90
|
|
56
|
ErbB2 overexpression in human breast carcinoma is correlated with p21Cip1 up-regulation and tyrosine-15 hyperphosphorylation of p34Cdc2: poor responsiveness to chemotherapy with cyclophoshamide methotrexate, and 5-fluorouracil is associated with Erb2 overexpression and with p21Cip1 overexpression.
|
Cancer
|
2003
|
0.90
|
|
57
|
Early placenta insulin-like growth factor (pro-EPIL) is overexpressed and secreted by c-erbB-2-positive cells with high invasion potential.
|
Cancer Res
|
2002
|
0.90
|
|
58
|
Novel approaches for chemosensitization of breast cancer cells: the E1A story.
|
Adv Exp Med Biol
|
2007
|
0.89
|
|
59
|
High prevalence of p53 exon 4 mutations in soft tissue sarcoma.
|
Cancer
|
2007
|
0.89
|
|
60
|
Prostate tumor cells infected with a recombinant influenza virus expressing a truncated NS1 protein activate cytolytic CD8+ cells to recognize noninfected tumor cells.
|
J Virol
|
2006
|
0.88
|
|
61
|
Expression of receptor tyrosine kinases epidermal growth factor receptor and HER-2/neu in synovial sarcoma.
|
Cancer
|
2005
|
0.88
|
|
62
|
Pilot and feasibility study: prospective proteomic profiling of mammary epithelial cells from high-risk women provides evidence of activation of pro-survival pathways.
|
Breast Cancer Res Treat
|
2011
|
0.86
|
|
63
|
Protein microarray analysis of mammary epithelial cells from obese and nonobese women at high risk for breast cancer: feasibility data.
|
Cancer Epidemiol Biomarkers Prev
|
2011
|
0.86
|
|
64
|
Cytoplasmic expression of p21CIP1/WAF1 is correlated with IKKbeta overexpression in human breast cancers.
|
Int J Oncol
|
2006
|
0.85
|
|
65
|
Activation of p21(CIP1/WAF1) in mammary epithelium accelerates mammary tumorigenesis and promotes lung metastasis.
|
Biochem Biophys Res Commun
|
2010
|
0.84
|
|
66
|
Characterization of 11 human sarcoma cell strains: evaluation of cytogenetics, tumorigenicity, metastasis, and production of angiogenic factors.
|
Cancer
|
2002
|
0.84
|
|
67
|
Inhibition of type I insulin-like growth factor receptor signaling attenuates the development of breast cancer brain metastasis.
|
PLoS One
|
2013
|
0.83
|
|
68
|
Enhanced PI3K p110α signaling confers acquired lapatinib resistance that can be effectively reversed by a p110α-selective PI3K inhibitor.
|
Mol Cancer Ther
|
2013
|
0.83
|
|
69
|
Activation of murine double minute 2 by Akt in mammary epithelium delays mammary involution and accelerates mammary tumorigenesis.
|
Cancer Res
|
2010
|
0.83
|
|
70
|
14-3-3zeta/tau heterodimers regulate Slingshot activity in migrating keratinocytes.
|
Biochem Biophys Res Commun
|
2009
|
0.82
|
|
71
|
Growth factor signaling in metastasis: current understanding and future opportunities.
|
Cancer Metastasis Rev
|
2012
|
0.81
|
|
72
|
Invasive breast cancer development: "fatal accident" from malfunctions in both "motor" and "brake".
|
Cell Cycle
|
2010
|
0.78
|
|
73
|
PI3K-independent mTOR activation promotes lapatinib resistance and IAP expression that can be effectively reversed by mTOR and Hsp90 inhibition.
|
Cancer Biol Ther
|
2015
|
0.77
|
|
74
|
Silibinin: a thorny therapeutic for EGF-R expressing tumors?
|
Cancer Biol Ther
|
2003
|
0.77
|
|
75
|
Tumor progression and metastasis from genetic to microenvironmental determinants: a workshop of the tumor progression and metastasis NIH study section in honor of Dr. Martin L. Padarathsingh, May 31, 2006, Georgetown, Washington, DC.
|
Cancer Biol Ther
|
2006
|
0.76
|
|
76
|
Oxygen sensor boosts growth factor signaling.
|
Nat Med
|
2009
|
0.76
|
|
77
|
PI3K: Missense Mutation Motivates Malignancy.
|
Cancer Biol Ther
|
2004
|
0.76
|
|
78
|
Liposomal mediated transfer of ErbB2 antisense DNA: coming of age in the war against cancer.
|
Cancer Biol Ther
|
2004
|
0.75
|
|
79
|
Adenoviral-Vector Based siRNA for Mutant K-ras as a Promising Tool for Lung Cancer Gene Therapy: A License to Kill.
|
Cancer Biol Ther
|
2006
|
0.75
|